Learn more

ONO PHARMACEUTICAL CO

Overview
  • Total Patents
    4,185
  • GoodIP Patent Rank
    2,952
  • Filing trend
    ⇩ 21.0%
About

ONO PHARMACEUTICAL CO has a total of 4,185 patent applications. It decreased the IP activity by 21.0%. Its first patent ever was published in 1962. It filed its patents most often in Japan, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are MARION MERRELL DOW INC, CONCENTRIC ANALGESICS INC and ASAHI KASEI PHARMA CORP.

Patent filings per year

Chart showing ONO PHARMACEUTICAL COs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Hayashi Masaki 319
#2 Shibayama Shiro 271
#3 Arai Yoshinobu 198
#4 Kobayashi Kaoru 177
#5 Takaoka Yoshikazu 142
#6 Nakai Hisao 140
#7 Tani Kousuke 125
#8 Takeuchi Jun 123
#9 Wakatsuka Hirohisa 120
#10 Maruyama Takayuki 117

Latest patents

Publication Filing date Title
WO2021080015A1 Modulators of trek (twik related k+ channels) channel function
WO2021080013A1 Inhibitors of trek (twik related k+ channels) channel function
WO2021043245A1 Hydantoin derivative
WO2021033729A1 Salt and crystal form of compound having agonistic activity to s1p5 receptor
WO2021025140A1 Dual-specific protein
WO2021025031A1 Biomarker for accessing efficacy of immune checkpoint inhibitor
WO2021020416A1 Bispecific antibody
WO2021010492A1 Compound having kdm5 inhibitory activity and pharmaceutical use thereof
WO2021006199A1 Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
WO2020262603A1 Ep2 antagonist
WO2020250940A1 Immunosuppression agent
WO2020116636A1 Immunosuppressant
WO2020111018A1 Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
WO2020059812A1 Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt
JP2020023490A Pharmaceutical composition including compound having somatostatin receptor actuation activity
WO2020027200A1 Therapeutic agent for cartilage disease
WO2020027150A1 Benzene derivative
WO2019240246A1 Novel salts and novel crystal forms of piperidinol derivatives
EP3789040A1 Preventive and/or therapeutic agent for autoimmune disease comprising compound having btk inhibitory activity as active ingredient
US2021087141A1 Compounds having s1p5 receptor agonistic activity